NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Beam Therapeutics Inc. BEAM
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$139.7M
▲ 120.0% vs FY2024
EPS · FY25
$-0.81
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-8.1%
Net margin · FY25
-57.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 139.7M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 57 cents on every revenue dollar this year.
Per share
USD -0.81
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-8.1%
Return on equity, FY2025
ROE
Operating margin-274.6%
Net margin-57.2%
Return on assets-6.2%
Each USD of equity lost 8 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+466.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+31.9%
+466.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years+77.7%
Change, 10 years—
The share count grew 78% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.5B
total assets, end of FY2025
Total assetsUSD 1.5B
EquityUSD 1.2B
CashUSD 294.9M
Current ratio13.09×
Equity funds 84% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.1
0.1
0.4
0.1
0.1
0.0
0.0
Operating income $B
−0.4
−0.4
−0.2
−0.3
−0.4
−0.1
−0.1
EBITDA $B
−0.4
−0.4
−0.2
−0.3
−0.4
−0.1
−0.1
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.4
−0.1
−0.3
−0.4
−0.2
−0.1
EPS, diluted $
−0.81
−4.58
−1.72
−4.13
−5.77
−4.19
−14.05
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−8.1
−43.9
−15.5
−37.1
−69.1
−875.4
·
Shares out B
0.10
0.08
0.08
0.07
0.07
0.06
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed